TIDMWDC
RNS Number : 6216R
WideCells Group PLC
25 September 2017
25 September 2017
WideCells Group PLC ('WideCells Group' or 'the Group')
Wideacademy: Development of a bespoke stem cell focused
educational platform
New Corporate Presentation and Attendance at Share Talk Investor
Evening
WideCells Group PLC, the healthcare services company focused on
providing stem cell services and ground-breaking insurance for stem
cell treatment, is pleased to announce that Wideacademy, its 100%
owned education and training division, has designed an innovative
Software as a Service ('Sas') platform (the 'Platform') to deliver
authentic, factual and trustworthy content on stem cell treatments
and life sciences. The Platform is currently being developed, with
commercial launch targeted for Q1 2018, and will aim to:
-- Inform the medical industry of the benefits of stem cell treatment;
-- Educate and inform consumers on stem cell innovation and best practice; and
-- Partner with enterprise, within both the stem cell and
insurance industry, to create training and digital resources.
The Platform is a unique, purpose built and intelligent
technology, created to enhance knowledge sharing, personal learning
journeys, and Continuing Professional Development ('CPD'). It has
contextual search functionality, meaning it is responsive and can
deliver personalised content relevant to each user's interest
and/or requirement. Combining free-to-access educational areas with
paid for premium digital tools and Artificial Intelligence ('AI'),
the Platform has a tripartite structure and monetisation
strategy:
-- Sponsorship: for an estimated annual membership cost starting
at GBP120 per doctor / medical professional, sponsors will be able
to gain access to the Premium Platform, which includes high-end
content, digital tools, peer-to-peer collaboration, AI and
dashboard reporting in support of stem cell innovation and
education.
-- Courseware and Accreditation:
o two types of courseware focussed on stem cells and life
sciences will be offered, which will be free to access to promote
learning and uptake:
-- modular - disseminated from long courses provided by
reputable academic partners (including leading universities),
targeted primarily at medical professionals; and
-- bespoke - built by Wideacademy in collaboration with academic
institutions, targeted primarily at people in enterprise.
o For both types of courseware there will be an opportunity for
accreditation, whereby Micro Credentials can be awarded in
recognition of competency-based professional development.
Accreditation is expected to be charged at around GBP200 per
module.
-- Platform Licence: Whilst current development of the Platform
is focused on the stem cell industry, the Company has identified
opportunities to white label it to support development in other
industries / areas of medicine.
Spearheading the development of the Platform is Alan Greenberg,
former Director of Education at Apple, who has extensive experience
and proven success in combining technology and education to deliver
engaging and authentic content to drive learning and development.
Mr. Greenberg will leverage his knowledge and global contact base
to help facilitate the roll-out of the Platform. This will include
securing strategic partnerships with leading global technology
companies / software providers. The Platform will initially be
delivered in English, but international roll-out is targeted.
An initial test version of the Platform is targeted to be made
live by the end of 2017, with a more final version available during
Q1 2018. The Company expects maiden revenues to commence in H1 2018
and is targeting 1,000 Sponsorships and the purchase of 2,000
modules by the end of 2018.
Wideacademy Director, Alan Greenberg, said, "Since joining
Wideacademy in February 2017 we have progressed from vision to
strategy and now to commercialisation and materialisation. We have
built a platform that permits learning journeys tailored to the
needs of the individual. It is an intelligent platform with
contextual search and AI functionality, that is crucially
adaptable. One platform is able to satisfy any and all needs of
both the professional and personal interest. This is game changing
technology that supports innovation."
WideCells Group CEO, João Andrade, said, "We firmly believe that
knowledge is power and having identified the huge life-saving
potential of stem cells, our focus is now on sharing this
understanding with the wider world. By combining education and
technology we hope that our platform will see Wideacademy become
the trusted thought leader and go-to resource in the stem cell
industry, helping people make informed choices on their medical
treatment and support industry development. With his unrivalled
skill set and experience in delivering tech based educational
products and services, Alan is undoubtedly the right man to be
developing and driving forward this highly innovative
proposition."
Further Information on the Wideacademy Platform
The Platform is designed to connect innovators, practitioners
and consumers in the belief that knowledge sharing and education
produce better health outcomes. Through the Platform Wideacademy
aims to:
-- Educate the medical world by providing:
o Validated information
o Authentic case studies
o Academic papers
o Credible experts
o CPD accredited courses
-- Educate parents with:
o Relevant, accessible information
o Validated resources
o A guide to available treatments
o Case studies
o Overview of risks and benefits
-- Demonstrate integrity to parents and doctors by only giving visibility to accredited:
o Cord blood banks
o Treatment centres
o Research labs
o CellPlan partners
o Insurance brokers
Investor Evening Attendance and New Corporate Presentation
WideCells Group is pleased to confirm its attendance at the
Share Talk Investor Evening in London on 27 September 2017. At the
conference, Group CEO João Andrade will give a presentation
outlining recent corporate developments and his plans for the
Group's future. For further information on the event or to register
your attendance please use the following link:
https://www.eventbrite.co.uk/e/investors-evening-regency-mines-widecells-group-vast-resources-tickets-28740408335
In conjunction with this event, there will be a new corporate
presentation, which will be uploaded onto the website on 27
September 2017. The presentation will be available to view here:
http://www.widecellsgroup.com/investor/corporate-documents
**ENDS**
For further information, please visit the Company's website
www.widecellsgroup.com, follow us on Twitter @WideCells_Group or
contact:
WideCells Group CEO - João Andrade Tel: +351 919
033 171
------------------- ------------------------ --------------
Smaller Company Broker-Jeremy Woodgate Tel: +44 (0)
Capital Ltd & Rupert Williams 20 3651 2912
------------------- ------------------------ --------------
Shard Capital Broker - Damon Heath Tel: +44 (0)
Partners LLP & Erik Woolgar 207 186 9950
------------------- ------------------------ --------------
St Brides Partners PR - Charlotte Page Tel: +44 (0)
Ltd & Olivia Vita 20 7236 1177
------------------- ------------------------ --------------
Notes to Editors
WideCells Group PLC is building an integrated stem cell services
company, focused on making stem cell treatments accessible and
affordable. In June 2017, the Group was ranked as the 21st most
disruptive company globally by DISRUPT 100, an annual index
celebrating the businesses with the most potential to influence,
change or create new global markets.
With this in mind, it has created three divisions:
-- CellPlan: the world's first stem cell healthcare insurance
plan with financial cover for medical treatment, travel and
accommodation expenses and concierge service to manage the
treatment process
-- WideCells: the Institute of Stem Cell Technology has been
established and is based in the University of Manchester Innovation
Centre to focus on stem cell research and regenerative medicine.
WideCells also has international cryogenics divisions specialising
in stem cell storage.
-- Wideacademy: developing an education and training division to
promote awareness of the benefits of stem cell storage across the
global general practice community.
The Group has built an experienced senior management team that
has been integral to the development of its growth and business to
date.
Stem Cell Fast Facts:
-- Cord blood (which is taken from the umbilical cord) provides
the most effective source of stem cells for families due to it
being simple, safe and painless to collect relative to other
sources of stem cells such as bone marrow - WideCells will focus on
promoting the collection and storage of this.
-- Since 2005, there has been a 300% increase in the number of
illnesses that can be treated using stem cells
-- 82 illnesses can currently be treated using stem cell procedures
-- Despite initial storage often costing no more than a few
GBPthousand, actual treatment can cost in the GBPhundreds of
thousands
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZMGZLKZLGNZM
(END) Dow Jones Newswires
September 25, 2017 02:00 ET (06:00 GMT)
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Mar 2024 to May 2024
Iconic Labs (LSE:ICON)
Historical Stock Chart
From May 2023 to May 2024